Levomepromazine Orion (Levomepromazine)
Phenothiazine antipsychotic for schizophrenia, psychosis, and severe pain management
Levomepromazine Orion contains the active ingredient levomepromazine, a phenothiazine-class antipsychotic medication used primarily in the treatment of severe psychiatric disorders including schizophrenia and other psychoses. It is also employed in the management of severe pain, either as a standalone treatment or as an adjunct to other analgesic medications. This comprehensive guide covers uses, dosage, side effects, drug interactions, and important safety information based on international medical guidelines.
Quick Facts About Levomepromazine Orion
Key Takeaways About Levomepromazine Orion
- Primary use: Levomepromazine is a phenothiazine antipsychotic used to treat severe psychiatric disorders such as schizophrenia and psychosis, and is also effective in managing severe pain conditions.
- Broad receptor activity: It blocks dopamine, serotonin, histamine, and adrenergic receptors, producing antipsychotic, sedative, analgesic, and antiemetic effects in a single medication.
- Serious safety concerns: Watch for signs of neuroleptic malignant syndrome (NMS), tardive dyskinesia, agranulocytosis, and QT prolongation — all require immediate medical attention.
- Alcohol avoidance: Alcohol must be avoided completely during treatment due to the risk of dangerous central nervous system depression and cardiovascular effects.
- Special populations: Elderly patients require lower doses due to increased sensitivity to side effects; the medication is not recommended for children or adolescents.
What Is Levomepromazine Orion and What Is It Used For?
Levomepromazine Orion is an antipsychotic medication belonging to the phenothiazine class, prescribed primarily for severe psychiatric disorders including schizophrenia and other psychoses. It can also be used to manage severe pain, either alone or in combination with analgesics to enhance their effectiveness.
Levomepromazine, the active ingredient in Levomepromazine Orion, is one of the older and more broadly acting antipsychotic medications available. Originally developed in the mid-20th century, it remains a valuable treatment option due to its unique pharmacological profile. Unlike many newer antipsychotics that primarily target dopamine receptors, levomepromazine exerts effects across multiple receptor systems in the central nervous system, giving it a distinctive combination of therapeutic properties.
The medication works by reducing the activity of several key neurotransmitters in the brain, most notably dopamine and serotonin. By blocking dopamine D2 receptors in the mesolimbic pathway, levomepromazine helps to alleviate the positive symptoms of psychosis, including hallucinations (hearing voices or seeing things that are not present), delusions (fixed false beliefs), and disordered thinking. This dopamine-blocking action is the primary mechanism underlying its antipsychotic effect, shared with other medications in the phenothiazine class.
Beyond its antipsychotic properties, levomepromazine has significant sedative, analgesic (pain-relieving), and antiemetic (anti-nausea) effects. The sedative properties arise primarily from blockade of histamine H1 receptors and alpha-1 adrenergic receptors, while the analgesic effects are thought to involve modulation of serotonin pathways in the spinal cord and brainstem. These combined properties make levomepromazine particularly useful in palliative care settings, where patients often experience a combination of agitation, pain, nausea, and distress that can be addressed simultaneously with a single medication.
In clinical practice, levomepromazine is used in several contexts. Its primary indication is for the treatment of severe mental health disorders, particularly schizophrenia and acute psychotic episodes. However, it is also widely used in pain management, especially for chronic or treatment-resistant pain conditions where conventional analgesics alone are insufficient. The medication can enhance the effectiveness of opioid and non-opioid painkillers when used as an adjunct. In palliative and end-of-life care, levomepromazine is considered an essential medication by many international guidelines due to its ability to manage multiple distressing symptoms concurrently.
Levomepromazine Orion may also be approved for the treatment of other conditions not specifically mentioned in this guide. Always consult your doctor, pharmacist, or other healthcare professional if you have questions about your prescription, and follow their instructions carefully.
What Should You Know Before Taking Levomepromazine Orion?
Before starting Levomepromazine Orion, your doctor must be informed of your complete medical history, current medications, and any allergies. There are several absolute contraindications and numerous conditions that require special caution during treatment.
Contraindications
Levomepromazine Orion must not be used under the following circumstances. If any of these apply to you, inform your doctor immediately as the medication cannot be safely prescribed:
- Allergy to levomepromazine or any of the other ingredients in the tablet (including lactose monohydrate, maize starch, gelatin, glycerol, talc, magnesium stearate, or sodium starch glycolate)
- Pheochromocytoma — a tumor of the adrenal glands that produces excessive adrenaline. Levomepromazine can trigger a dangerous hypertensive crisis in patients with this condition
- Bone marrow disorders — conditions affecting blood cell production, as levomepromazine can further suppress bone marrow function
- Brain injury — acute traumatic or structural brain damage, as the medication may worsen intracranial pressure and neurological function
- History of neuroleptic malignant syndrome (NMS) — a rare but life-threatening reaction to antipsychotic medications characterized by fever, muscle rigidity, and altered consciousness
- Myasthenia gravis — a condition causing progressive muscle weakness, which can be exacerbated by levomepromazine
- Active alcohol use — concurrent alcohol consumption is contraindicated due to dangerous synergistic central nervous system depression
Warnings and Precautions
Before and during treatment with Levomepromazine Orion, speak with your doctor or pharmacist if you have or have ever had any of the following conditions, as they may require dose adjustments, additional monitoring, or alternative treatment strategies:
- Central nervous system disorders such as epilepsy (seizure disorder), history of stroke, or dementia. Levomepromazine lowers the seizure threshold and may increase the risk of cerebrovascular events
- Cardiovascular disease including heart failure, coronary artery disease, or arrhythmias. The medication can cause orthostatic hypotension and QT prolongation
- Liver or kidney disease which may affect drug metabolism and elimination, potentially leading to drug accumulation and increased toxicity
- Respiratory disease such as chronic obstructive pulmonary disease (COPD) or asthma, as the sedative effects may suppress breathing
- Hypothyroidism (underactive thyroid), which can increase sensitivity to the sedative effects of levomepromazine
- Diabetes mellitus — levomepromazine may alter blood sugar regulation, requiring closer monitoring of glucose levels
- Glaucoma (narrow-angle type) — the anticholinergic properties of levomepromazine can increase intraocular pressure
- Parkinson's disease — the dopamine-blocking action of levomepromazine can worsen parkinsonian symptoms
- QT prolongation (personal or family history) — levomepromazine may further prolong the QT interval on ECG, increasing the risk of serious cardiac arrhythmias
- History of blood clots (personal or family) — antipsychotic medications have been associated with an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism
- Bradycardia (slower than normal heart rate), which may increase the risk of QT-related cardiac events
- Prostatic hyperplasia (enlarged prostate) — the anticholinergic effects may worsen urinary retention
- Tardive dyskinesia — if you have existing involuntary movements, the medication may worsen or perpetuate them
Levomepromazine Orion can cause significant dry mouth (xerostomia), which, if persistent during long-term treatment, may lead to dental caries, gum disease, and oral mucosal damage. Brush teeth thoroughly with fluoride toothpaste at least twice daily, use saliva-stimulating products as needed, and attend regular dental check-ups to prevent oral complications.
Elderly Patients
Doses for elderly patients are typically lower than for other adults due to increased sensitivity to adverse effects, particularly orthostatic hypotension (dangerous drops in blood pressure upon standing), excessive sedation, and extrapyramidal symptoms. In elderly patients with dementia, a small increased risk of death has been observed with antipsychotic medications compared to placebo in clinical studies. The decision to use levomepromazine in this population should be carefully weighed against the potential risks, and treatment should be regularly reviewed.
Children and Adolescents
Levomepromazine Orion is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of levomepromazine has not been sufficiently established in pediatric populations. Children requiring antipsychotic treatment should be evaluated by specialist child and adolescent psychiatry services, where appropriate medications with established pediatric safety profiles can be prescribed.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using Levomepromazine Orion. The medication is generally not recommended during pregnancy or breastfeeding unless the prescribing physician considers it essential for the mother's health and the benefits clearly outweigh the potential risks to the baby.
Newborn babies whose mothers used Levomepromazine Orion during the third trimester (last three months) of pregnancy may experience withdrawal symptoms including tremors, muscle stiffness or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If your baby develops any of these symptoms after birth, contact a doctor promptly.
Levomepromazine passes into breast milk, so breastfeeding should be discontinued during treatment to avoid potential effects on the nursing infant. Discuss alternative feeding options with your healthcare team if antipsychotic treatment is necessary.
Driving and Operating Machinery
Levomepromazine Orion causes drowsiness and can significantly impair reaction times and cognitive function. This must be taken into account when activities requiring alertness are undertaken, including driving and operating heavy machinery. During the first weeks of treatment, you are strongly advised to avoid driving and operating machinery until you understand how the medication affects your alertness and coordination. You are always personally responsible for assessing whether you are fit to drive or perform tasks requiring sharp focus.
Levomepromazine Orion 25 mg tablets contain 43 mg of lactose (as monohydrate). If you have been diagnosed with an intolerance to certain sugars, consult your doctor before taking this medication. The tablets also contain less than 1 mmol (23 mg) of sodium per tablet, meaning they are essentially sodium-free.
How Does Levomepromazine Orion Interact with Other Drugs?
Levomepromazine interacts with numerous medications, particularly other central nervous system depressants, drugs that prolong the QT interval, and medications that affect electrolyte balance. Always inform your doctor of all medications you are taking, including prescription drugs, over-the-counter products, and herbal supplements.
Drug interactions with levomepromazine are clinically significant and can lead to dangerous additive or synergistic effects. The broad receptor-binding profile of levomepromazine means it can interact with a wide range of medications across different therapeutic classes. Special caution is required when levomepromazine is combined with medicines known to affect the body's electrolyte balance (particularly potassium levels) or to prolong the QT interval on electrocardiogram (ECG), as this combination can increase the risk of life-threatening cardiac arrhythmias.
| Drug / Drug Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Other antipsychotics (thioridazine, sertindole) | Major | Additive QT prolongation, excessive CNS depression, increased risk of arrhythmias | Avoid combination; if essential, ECG monitoring required |
| Sedatives and hypnotics (benzodiazepines, Z-drugs) | Major | Enhanced sedation, respiratory depression, profound hypotension | Use lowest effective doses; monitor closely |
| Opioid analgesics (codeine, methadone) | Major | Enhanced sedation, respiratory depression; methadone also prolongs QT | Dose reduction of both agents; respiratory monitoring |
| Antidepressants (venlafaxine, paroxetine, fluoxetine, clomipramine) | Moderate to Major | Increased levomepromazine levels (CYP2D6 inhibition), enhanced sedation, serotonin-related effects | Monitor for toxicity; dose adjustment may be needed |
| Antihypertensives (ACE inhibitors, beta-blockers) | Moderate | Enhanced hypotensive effect, increased risk of orthostatic hypotension and falls | Blood pressure monitoring; gradual dose titration |
| Anticonvulsants (carbamazepine, phenytoin) | Moderate | Lowered seizure threshold; anticonvulsant levels may be altered | Monitor seizure control; adjust anticonvulsant dose as needed |
| Lithium | Moderate | Increased risk of neurotoxicity and extrapyramidal symptoms | Monitor lithium levels and neurological status |
| Levodopa, bromocriptine, cabergoline | Moderate | Reduced effectiveness of anti-Parkinsonian medications due to dopamine receptor blockade | Generally avoid combination; re-evaluate treatment plan |
| Quinidine | Major | Additive QT prolongation; increased risk of torsades de pointes | Avoid combination; ECG monitoring if unavoidable |
| Antihistamines (sedating types) | Moderate | Additive sedation, anticholinergic effects, increased drowsiness | Use non-sedating antihistamines when possible |
Avoid all alcohol consumption during treatment with Levomepromazine Orion. Alcohol significantly amplifies the sedative and hypotensive effects of levomepromazine, increasing the risk of dangerous drowsiness, respiratory depression, falls, and cardiovascular complications.
Food Interactions
Levomepromazine Orion tablets can be taken with or without food. There are no specific dietary restrictions beyond the absolute prohibition of alcohol. Grapefruit juice may theoretically affect the metabolism of some phenothiazines, though this interaction is not well-documented for levomepromazine specifically. If you consume grapefruit regularly, mention this to your prescribing physician.
What Is the Correct Dosage of Levomepromazine Orion?
The dose of Levomepromazine Orion is determined individually by your doctor based on your condition, age, and response to treatment. The tablet is scored and can be divided into two equal halves for flexible dosing. Always follow your doctor's instructions precisely.
Levomepromazine dosing is highly individualized. The prescribing physician will determine the optimal dose based on the specific condition being treated, the severity of symptoms, the patient's age and weight, kidney and liver function, concurrent medications, and the individual response to treatment. Doses are typically started low and gradually increased to achieve the desired therapeutic effect while minimizing side effects.
| Patient Group | Indication | Typical Starting Dose | Usual Maintenance Dose | Notes |
|---|---|---|---|---|
| Adults | Psychosis / Schizophrenia | 25–50 mg/day | 75–200 mg/day (divided doses) | Doses up to 1000 mg/day have been used in severe cases under specialist supervision |
| Adults | Severe pain (adjuvant) | 12.5–25 mg/day | 25–75 mg/day | Used alongside primary analgesics; lower doses for analgesic augmentation |
| Adults | Palliative care (nausea/agitation) | 6.25–12.5 mg | 12.5–25 mg/day | Antiemetic and sedative effects at lower doses |
| Elderly | All indications | Lower doses (as directed) | Lower than adult doses | Increased sensitivity to side effects; start low and titrate slowly |
| Children/Adolescents | N/A | Not recommended | Not recommended | Safety and efficacy not established in patients under 18 years |
Missed Dose
What to Do If You Miss a Dose
Take the missed dose as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Never take a double dose to compensate for a forgotten one, as this significantly increases the risk of side effects including excessive sedation and dangerous drops in blood pressure. If you are traveling, ensure you pack sufficient medication for the entire duration of your trip.
Overdose
If you have taken too much Levomepromazine Orion, or if a child has accidentally ingested the medication, contact your local emergency services or poison control center immediately. Symptoms of overdose may include extreme drowsiness, loss of consciousness, severe hypotension, respiratory depression, seizures, and cardiac arrhythmias. Always bring the medication packaging with you when seeking emergency help, whether or not any tablets remain.
Stopping Treatment
Do not stop taking Levomepromazine Orion without consulting your doctor. Abrupt discontinuation of antipsychotic medications can lead to withdrawal symptoms including nausea, vomiting, sweating, insomnia, and a potential relapse of the underlying psychiatric condition. Your doctor will typically plan a gradual dose reduction over several weeks to safely discontinue the medication.
What Are the Side Effects of Levomepromazine Orion?
Like all medications, Levomepromazine Orion can cause side effects, though not everyone will experience them. The most common side effects include drowsiness, dizziness, orthostatic hypotension (blood pressure drop on standing), dry mouth, and extrapyramidal symptoms. Some side effects are serious and require immediate medical attention.
At the start of treatment, you may experience dizziness and lightheadedness when standing up, particularly from a lying or sitting position. These symptoms typically diminish as your body adjusts to the medication over the first few weeks. Rising slowly from bed or from a chair can help minimize this effect.
Neuroleptic malignant syndrome (NMS): High fever, excessive sweating, muscle rigidity, mood changes, irregular heartbeat, and unstable blood pressure. This is a life-threatening emergency that requires immediate hospital treatment.
Tardive dyskinesia: Involuntary, rhythmic movements of the tongue, face, mouth, or jaw, sometimes accompanied by involuntary movements of the arms and legs.
Agranulocytosis: Signs of serious infection (sore throat, fever, significant deterioration in general condition, urinary symptoms) that may indicate a dangerous drop in white blood cells.
Anaphylactic shock: Rapid onset of itching or rash, swelling of face, lips, tongue, or throat, difficulty breathing, and rapid drop in blood pressure.
Very Common / Common
Very common: may affect more than 1 in 10 people | Common: up to 1 in 10 people
- Dizziness, drowsiness, and fatigue
- Involuntary movements (tardive dyskinesia) and tremor around the mouth (with long-term use)
- Parkinson-like symptoms (tremor, rigidity, shuffling gait)
- Motor restlessness and inability to sit still (akathisia)
- Mild blood count changes
- Increased heart rate (tachycardia)
- Blood pressure drop (orthostatic hypotension)
- Dry mouth (xerostomia)
- Skin reactions (hives, rash, itching, photosensitivity)
Uncommon
May affect up to 1 in 100 people
- Blurred vision
- Constipation
- Difficulty urinating (urinary retention)
- Menstrual irregularities
- Breast swelling and tenderness (gynecomastia)
Rare / Very Rare
Rare: up to 1 in 1,000 people | Very rare: up to 1 in 10,000 people
- Severe blood count changes (agranulocytosis, pancytopenia)
- Altered sugar sensitivity, appetite changes, weight gain
- Memory difficulties
- Sudden involuntary muscle movements or spasms (dystonia)
- Seizures
- Worsened narrow-angle glaucoma
- Clouding of the lens or cornea
- Irregular heartbeat, cardiac arrest
- Jaundice (yellowing of the skin and eyes)
- Neuroleptic malignant syndrome (fever, reduced consciousness, muscle rigidity)
- Increased body hair (hirsutism)
- Changes in libido, delayed orgasm, erectile dysfunction
- Painful prolonged erection (priapism)
Frequency Not Known
Reported but frequency cannot be determined from available data
- Venous thromboembolism (pulmonary embolism and deep vein thrombosis)
- Anaphylactic shock (severe allergic reaction)
Among elderly patients with dementia, a small increase in the number of deaths has been reported for those treated with antipsychotic medications compared to those who did not receive antipsychotic treatment. This observation applies to antipsychotics as a class and should be discussed with the prescribing physician when considering treatment in this population.
If any side effects become troublesome, or if you notice any side effects not listed in this information, contact your doctor or pharmacist. Reporting side effects helps to provide more information on the safety of medicines. In the United Kingdom, side effects can be reported to the MHRA via the Yellow Card Scheme; in the European Union, reporting can be done through your national pharmacovigilance authority; in the United States, contact the FDA MedWatch program.
How Should You Store Levomepromazine Orion?
Store Levomepromazine Orion tablets at room temperature, not exceeding 30°C (86°F), in the original packaging to protect from light. Keep out of the sight and reach of children.
Proper storage is essential to maintain the potency and safety of Levomepromazine Orion throughout its shelf life. The active ingredient, levomepromazine, is sensitive to light and may degrade if exposed to prolonged or intense illumination. Always keep the tablets in their original blister packaging or container until you are ready to take a dose.
Do not use the tablets after the expiry date printed on the outer carton and the blister pack. The expiry date refers to the last day of the stated month. Check this date before taking each new pack of medication.
Unused or expired medicines should not be discarded via household waste or flushed down the toilet, as pharmaceutical compounds can persist in the environment and contaminate water supplies. Instead, return any unwanted medications to your local pharmacy, which can dispose of them safely in accordance with environmental protection regulations.
Storage Summary
- Temperature: Store at or below 30°C (86°F)
- Light protection: Keep in original packaging (light-sensitive)
- Child safety: Keep out of the sight and reach of children
- Expiry: Do not use after the expiry date stated on the packaging
- Disposal: Return unused tablets to a pharmacy; do not discard in household waste or wastewater
What Does Levomepromazine Orion Contain?
Each Levomepromazine Orion 25 mg tablet contains 25 mg of the active substance levomepromazine along with several inactive ingredients (excipients) necessary for tablet manufacture. The tablets are white or almost white, flat with beveled edges, scored, and marked "ORN 16."
Active Ingredient
Each tablet contains 25 mg of levomepromazine (also known as methotrimeprazine in some countries). Levomepromazine is a phenothiazine derivative with a broad pharmacological profile, exerting effects on dopaminergic, serotonergic, histaminergic, adrenergic, and cholinergic receptor systems.
Inactive Ingredients (Excipients)
The non-active components of the tablet serve various purposes in the manufacturing process, including binding, filling, lubricating, and facilitating disintegration of the tablet in the gastrointestinal tract. They include:
- Lactose monohydrate (43 mg per 25 mg tablet) — filler
- Maize starch — disintegrant and filler
- Gelatin — binder
- Glycerol (85%) — plasticizer
- Talc — glidant and anti-adherent
- Magnesium stearate — lubricant
- Sodium starch glycolate (type C) — super-disintegrant
Tablet Description
| Characteristic | 25 mg Tablet |
|---|---|
| Color | White or almost white |
| Shape | Flat with beveled edges |
| Score line | Yes (can be divided into equal halves) |
| Marking | ORN 16 |
| Diameter | 7 mm |
Pack Sizes
Levomepromazine Orion 25 mg tablets are available in packs of 30, 50, 84, and 100 tablets. Not all pack sizes may be marketed in all countries. The marketing authorization holder and manufacturer is Orion Corporation, based in Espoo, Finland. The medication is approved in several European Economic Area (EEA) member states, where it may be marketed under different national names.
Frequently Asked Questions About Levomepromazine Orion
Levomepromazine is distinguished from other antipsychotics by its exceptionally broad receptor-binding profile. While most antipsychotics primarily target dopamine D2 receptors, levomepromazine also has significant activity at serotonin, histamine, adrenergic, and muscarinic receptors. This gives it a unique combination of antipsychotic, sedative, analgesic, and antiemetic properties in a single molecule. This broad profile makes it particularly useful in palliative care, where multiple symptoms need to be managed simultaneously. However, it also means levomepromazine tends to cause more side effects (especially sedation and orthostatic hypotension) compared to more selective antipsychotics.
While levomepromazine has strong sedative properties and is sometimes used off-label for insomnia or sleep disturbances in certain clinical contexts (particularly in palliative care), it is not typically recommended as a first-line treatment for sleep disorders. The medication carries significant side effect risks including metabolic effects, movement disorders, and cardiovascular effects that make it unsuitable for routine insomnia management. Safer, more targeted sleep medications are available. If you are experiencing sleep problems, discuss appropriate treatment options with your doctor rather than adjusting your levomepromazine dose independently.
The sedative effects of levomepromazine are typically felt within 30 minutes to 1 hour after oral administration and can last for several hours. However, the full antipsychotic effect develops more gradually over the course of several days to weeks of regular treatment, as the medication reaches steady-state levels in the body and the underlying neurochemical imbalances begin to stabilize. Pain-relieving effects are generally noticeable within the first few days of treatment. Your doctor will schedule follow-up appointments to assess your response and adjust the dose as needed during the initial treatment period.
Levomepromazine is not considered an addictive medication in the traditional pharmacological sense. It does not produce euphoria or the reward-seeking behavior associated with substances of abuse such as opioids or benzodiazepines. However, your body may develop a degree of physiological adaptation to the medication over time, which is why it is important not to stop treatment abruptly. Sudden discontinuation can lead to withdrawal symptoms including nausea, sweating, and insomnia, as well as a potential relapse of the underlying psychiatric condition. Always work with your doctor to plan any changes to your treatment regimen.
Yes, Levomepromazine Orion tablets can be taken with or without food. Taking the tablet with a meal or a glass of water may help reduce the chance of stomach upset. There are no specific foods that you need to avoid while taking levomepromazine, with the important exception of alcohol, which must be completely avoided throughout treatment. If you experience gastrointestinal discomfort when taking the medication, try taking it with a snack or meal and discuss persistent symptoms with your pharmacist or doctor.
Orthostatic hypotension (dizziness on standing) is a common side effect, especially at the start of treatment. To minimize this: rise slowly from lying or sitting positions, sit on the edge of the bed for a few moments before standing, stay well hydrated, and avoid hot baths or showers. If dizziness is severe, persistent, or causes fainting episodes, contact your doctor as your dose may need adjustment. This side effect usually improves over the first few weeks as your body adjusts to the medication, but it should always be reported to your healthcare team.
References and Sources
This article is based on evidence-based medical information from the following peer-reviewed sources and authoritative guidelines:
- European Medicines Agency (EMA). Summary of Product Characteristics: Levomepromazine. European Medicines Agency, 2024. Available at: www.ema.europa.eu
- British National Formulary (BNF). Levomepromazine. National Institute for Health and Care Excellence (NICE), 2025. Available at: bnf.nice.org.uk
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. Geneva: World Health Organization, 2023.
- Taylor D, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 14th Edition. Wiley-Blackwell, 2021. ISBN: 978-1-119-77224-6.
- Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5th Edition. Cambridge University Press, 2021. ISBN: 978-1-108-83857-8.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 2013; 382(9896): 951-962. doi: 10.1016/S0140-6736(13)60733-3
- Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005; 294(15): 1934-1943. doi: 10.1001/jama.294.15.1934
- Prommer E. Levomepromazine: Is There a Role in Palliative Medicine? American Journal of Hospice and Palliative Medicine, 2020; 37(12): 1045-1050. doi: 10.1177/1049909120920541
- Brayfield A (ed.). Martindale: The Complete Drug Reference, 40th Edition. Pharmaceutical Press, 2020. ISBN: 978-0-85711-381-3.
- Orion Corporation. Product Information: Levomepromazine Orion 25 mg Tablets. Espoo, Finland: Orion Corporation, 2021.
About the iMedic Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians and clinical pharmacologists with expertise in psychiatry, psychopharmacology, and evidence-based medicine.
Medical Writing
Content developed by specialist physicians with clinical experience in psychiatry and pharmacology, following GRADE evidence framework and international prescribing guidelines.
Medical Review
All content independently reviewed by the iMedic Medical Review Board for clinical accuracy, completeness, and adherence to current international medical guidelines (EMA, BNF, WHO).
Editorial Standards: All iMedic content adheres to strict editorial standards including evidence-based sourcing, conflict-of-interest disclosure, regular review cycles, and transparent correction policies. We receive no commercial funding or pharmaceutical industry sponsorship. Learn more about our editorial standards.